MedTrace Logo

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

NCT05001269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-04-16

Study results available
· View outcomes & findings →

Summary

The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.

Conditions

  • Primary Hyperoxaluria
  • Primary Hyperoxaluria Type 1
  • Primary Hyperoxaluria Type 2
  • Primary Hyperoxaluria Type 3

Interventions

DRUG

nedosiran

Monthly subcutaneous dosing throughout study period

Sponsors & Collaborators

  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

    lead INDUSTRY

Principal Investigators

  • Sarb Shergill, PhD · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2025-02-05
Completion
2025-02-05
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Italy
  • Japan
  • Lebanon
  • Poland
  • Spain
  • Turkey (Türkiye)
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001269 on ClinicalTrials.gov